GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » Operating Margin %
中文

BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Operating Margin % : -45.68% (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. BioCryst Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-42.7 Mil. BioCryst Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $93.4 Mil. Therefore, BioCryst Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 was -45.68%.

Good Sign:

BioCryst Pharmaceuticals Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for BioCryst Pharmaceuticals's Operating Margin % or its related term are showing as below:

BCRX' s Operating Margin % Range Over the Past 10 Years
Min: -981.12   Med: -194.06   Max: -31.29
Current: -31.29


BCRX's Operating Margin % is ranked better than
65.89% of 1026 companies
in the Biotechnology industry
Industry Median: -177.195 vs BCRX: -31.29

BioCryst Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 42.70% per year.

BioCryst Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-42.7 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-103.7 Mil.


BioCryst Pharmaceuticals Operating Margin % Historical Data

The historical data trend for BioCryst Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Operating Margin % Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -203.66 -981.12 -113.08 -54.81 -31.29

BioCryst Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -58.22 -41.31 -25.10 -13.74 -45.68

Competitive Comparison of BioCryst Pharmaceuticals's Operating Margin %

For the Biotechnology subindustry, BioCryst Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCryst Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Operating Margin % falls into.



BioCryst Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

BioCryst Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-103.709 / 331.412
=-31.29 %

BioCryst Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-42.67 / 93.401
=-45.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioCryst Pharmaceuticals  (NAS:BCRX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


BioCryst Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Executives
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Jon P Stonehouse director, officer: CEO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Charles K Gayer officer: Vice President and CCO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Michael L Jones officer: Exec Director, Finance - PAO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes officer: VP, General Counsel & Corp Sec 1929 BRASSFIELD ROAD, RALEIGH NC 27614
Anthony Doyle officer: Chief Financial Officer 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu officer: VP Drug Discovery 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
George B Abercrombie director C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
William P Sheridan officer: SR VP - CMO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Amy E Mckee director 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Lee Kenneth B Jr director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Steven K Galson director C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703